Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Investigating the Safety of Fampridine in Patients With Different Stages of Multiple Sclerosis Publisher



Vaheb S1 ; Farzan M3 ; Afsharisafavi A4 ; Ebrahimi N1 ; Shaygannejad V1, 5 ; Mirmosayyeb O1, 5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Shahrekord University of Medical Sciences, Shahrekord, Iran
  3. 3. Medical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran
  4. 4. Department of Biostatistics and Epidemiology, Faculty of Health, North Khorasan University of Medical Sciences, Bojnurd, Iran
  5. 5. Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Source: International Journal of Preventive Medicine Published:2025


Abstract

Background: Fampridine is the only drug approved by the US Food and Drug Administration (FDA) for people with multiple sclerosis (MS) to improve their movement and has exhibited a clinically significant improvement in gait function in a subset of MS patients with Expanded Disability Status Scale (ESDSS) from 4 to 7. Nevertheless, this drug has been reported to possess some adverse effects (AEs) like seizure because of its pharmacological features. The aim of this study was to evaluate the incidence rate of post-medication side effects (SEs) of fampridine in MS patients. Methods: This prospective cohort study includes MS patients aged between 18 and 65 years, referred to the neurology clinic of Kashani Hospital from April 2022 to October 2022, all with administration of fampridine (10 mg tablet twice daily according to the product specifications). Safety in these patients was monitored through monthly SEs checklist questions during 6 months of screening. SPSS version 18 was used to analyze the data of this study. Results: From 319 participants screened at baseline, 254 patients with MS, including 127 relapsing-remitting multiple sclerosis (RRMS), 101 secondary progressive multiple sclerosis (SPMS), and 26 primary progressive multiple sclerosis (PPMS), were included in the study. The most observed AEs in SPMS and RRMS patients were dry mouth (13.9% vs. 15%) and insomnia (12.9% vs. 11%), respectively. Urinary tract infection (UTI) (11.5%) and stomachache (11.5%) were the most common SEs in PPMS patients. The most severe complication of the patients was back pain, while digestive complications were less severe. Also, insomnia and UTI were the patients' most persistent SEs. Conclusions: The drug seems to be safe and well tolerated, as the SEs were mild and transient and they were consistent with most of the previous studies focusing on this medication. © 2025 International Journal of Preventive Medicine.
Related Docs
View other Related Docs
1. The Effect of Fampridine on the Risk of Seizure in Patients With Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2020)
2. Confirmed Disability Progression As a Marker of Permanent Disability in Multiple Sclerosis, European Journal of Neurology (2022)
3. A Report of Multiple Sclerosis Patients Treated by Cinnovex™ in Iran, Tehran University Medical Journal (2010)
4. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis, Neurology (2022)
5. Comparing the Efficacy of Monthly Cyclophosphamide As Monotherapy Versus Daily Fingolimod in Relapsing Remitting and Secondary Progressive Multiple Sclerosis, Journal of Isfahan Medical School (2017)
6. Safety and Efficacy of Cladribine in Multiple Sclerosis: A Systematic Review and Meta-Analysis, Neurological Sciences (2023)
7. Seizure Characteristics in Multiple Sclerosis Patients, Journal of Research in Medical Sciences (2013)
8. Effect of Ms14® on Physical Activity of Multiple Sclerosis Patients: A Randomized Triple-Blind Placebo-Controlled Clinical Trial, Multiple Sclerosis and Related Disorders (2023)
Experts (# of related papers)
View all Related Experts
Vahid Shaygannejad (89)
Masoud Etemadifar (61)
Other Related Docs
9. Comparable Efficacy and Safety of Teriflunomide Versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis, Neurology Research International (2021)
10. Comparison of Fingolimod, Dimethyl Fumarate and Teriflunomide for Multiple Sclerosis, Journal of Neurology, Neurosurgery and Psychiatry (2019)
11. Comparison Effect of Prescription Drugs on the Occurrence and the Number of Attacks in Patients With Multiple Sclerosis, Journal of Isfahan Medical School (2018)
12. Cyclophosphamide Versus Rituximab in Progressive Forms of Multiple Sclerosis, Acta Medica Iranica (2019)
13. Safety and Effectiveness of Cinnomer® on Disease Characteristics, Depression, and Quality of Life of Patients With Multiple Sclerosis: A Phase Iv, Post-Marketing, Prospective, Multicenter Study, Archives of Iranian Medicine (2023)
14. Multiple Sclerosis in Isfahan, Iran, International Review of Neurobiology (2007)
15. Management of Seizures in Patients With Multiple Sclerosis; an Iranian Consensus, Epilepsy and Behavior (2019)
16. Effectiveness of Multiple Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis: Causal Inference to Emulate a Multiarm Randomised Trial, Journal of Neurology, Neurosurgery and Psychiatry (2023)
17. Side Effects of Methylprednisolone Pulse Therapy in Treatment of Multiple Sclerosis, Journal of Isfahan Medical School (2012)
18. Safety and Efficacy of Fingolimod in Iranian Patients With Relapsing-Remitting Multiple Sclerosis: An Open-Label Study, Caspian Journal of Internal Medicine (2021)
19. Seizure in Iranian Patients With Multiple Sclerosis, Journal of Research in Medical Sciences (2013)
20. Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis: A Randomized Clinical Trial, Acta Neurologica Scandinavica (2021)
21. Multiple Sclerosis-Related Fatigue Lacks a Unified Definition: A Narrative Review, Journal of Research in Medical Sciences (2022)
22. Epidemiology of Multiple Sclerosis in Iran: A Systematic Review, European Neurology (2013)
23. Effect of Mediterranean Diet on Body Mass Index and Fatigue Severity in Patients With Multiple Sclerosis: A Systematic Review and Meta-Analysis of Clinical Trials, Heliyon (2024)
24. Environmental Risk Factors for Multiple Sclerosis: A Case-Control Study in Kerman, Iran, Iranian Journal of Nursing and Midwifery Research (2018)
25. Tumefactive Rebound of Multiple Sclerosis After the Short-Term Cessation of Fingolimod: A Case Report, Multiple Sclerosis and Related Disorders (2020)
26. Early Clinical Response and Complications of Therapeutic Plasma Exchange in Central Nervous System Demyelinating Diseases, Journal of Central Nervous System Disease (2024)
27. A Mediterranean-Type Diet Improved Systemic Inflammation in Multiple Sclerosis Patients, As Compared to the Traditional Iranian Diet: A Single-Center Randomized Controlled Trial, Mediterranean Journal of Nutrition and Metabolism (2021)
28. Diagnosis and Management of Multiple Sclerosis in Children, Iranian Journal of Child Neurology (2016)
29. Contribution of Different Relapse Phenotypes to Disability in Multiple Sclerosis, Multiple Sclerosis (2017)
30. Neurological Efficacy and Safety of Mesenchymal Stem Cells (Mscs) Therapy in People With Multiple Sclerosis (Pwms): An Updated Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2024)
31. Serum Mercury Level and Multiple Sclerosis, Biological Trace Element Research (2012)
32. Risk Factors of Multiple Sclerosis and Their Relation With Disease Severity: A Cross-Sectional Study From Iran, Archives of Iranian Medicine (2016)
33. Investigating the Occurrence of Femoral Head Avascular Necrosis in Patient With Multiple Sclerosis Treated With Interferon-Beta, Journal of Isfahan Medical School (2018)
34. Thalamic Asymmetry in Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2023)
35. Comparison of Interferon Beta Products and Azathioprine in the Treatment of Relapsing-Remitting Multiple Sclerosis, Journal of Neurology (2007)
36. Prognostic Value of Intrathecal Igg Synthesis in Multiple Sclerosis: A Study in 54 Patients, Tehran University Medical Journal (2008)
37. Concurrent Glioma and Multiple Sclerosis: A Systematic Review of Case Reports, Multiple Sclerosis and Related Disorders (2024)
38. Serum Uric Acid Level in Patients With Relapsing-Remitting Multiple Sclerosis, Journal of Clinical Neuroscience (2013)
39. Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years, Multiple Sclerosis and Related Disorders (2022)
40. Co-Supplementation of Synbiotics and Anti-Inflammatory-Antioxidant Rich Diet in Patients With Progressive Forms of Multiple Sclerosis: A Single-Center, Randomized Clinical Trial, Mediterranean Journal of Nutrition and Metabolism (2024)
41. Comparison of the Effect of Aspirin and Amantadine for the Treatment of Fatigue in Multiple Sclerosis: A Randomized, Blinded, Crossover Study, Neurological Research (2012)
42. The Association Between Multiple Sclerosis and Migraine: A Meta-Analysis, Multiple Sclerosis and Related Disorders (2023)
43. Comparison of the Efficacy and Side Effects of Ifn Beta 1-A (Rebif) and a Biosimilar Product (Recigen) in Patients With Multiple Sclerosis, Journal of Isfahan Medical School (2012)
44. The Frequency of Cognitive Dysfunction Among Multiple Sclerosis Patients With Mild Physical Disability, Journal of Isfahan Medical School (2012)
45. Comparison of Cognitive Rehabilitation Versus Donepezil Therapy on Memory Performance, Attention, Quality of Life, and Depression Among Multiple Sclerosis Patients, Neurology Research International (2020)
46. The Prevalence of Restless Legs Syndrome (Rls) in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis—An Update, Neurological Sciences (2023)
47. Anti-Cd20 Therapies for Pediatric-Onset Multiple Sclerosis: A Systematic Review, Multiple Sclerosis and Related Disorders (2024)
48. Th1, Th2 and Th17 Cytokine Profile in Patients With Multiple Sclerosis Following Treatment With Rapamycin, Iranian Journal of Immunology (2016)
49. Prevalence of Familial Multiple Sclerosis in Isfahan, Iran, Journal of Isfahan Medical School (2011)
50. The Effectiveness of Natalizumab Vs Fingolimod–A Comparison of International Registry Studies, Multiple Sclerosis and Related Disorders (2021)